Phase II trial of piroxantrone in advanced non-small cell carcinoma of the lung. A Southwest Oncology Group study.
Williamson
S K
SK
University of Kansas Medical Center, Kansas City.
Crowley
J J
JJ
Livingston
R
R
Hantel
A
A
Doroshow
J H
JH
D000328:Adult; D000368:Aged; D000880:Anthraquinones / Q000008:administration & dosage* / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011720:Pyrazoles / Q000008:administration & dosage* / Q000009:adverse effects
D000880:Anthraquinones; D000970:Antineoplastic Agents; D011720:Pyrazoles; C046659:piroxantrone